Tyvyt (sintilimab Injection), an innovative PD-1 inhibitor jointly developed by Innovent and Lilly, is included in the new catalogue of National Reimbursement Drug List

Innovent Biologics

27 November 2019 - Innovent Biologics today jointly announced with Eli Lilly and Company that the innovative PD-1 inhibitor Tyvyt (sintilimab injection), co-developed by both companies, is the only PD-1 inhibitor that has been included in the new Catalogue of National Reimbursement Drug List according to the latest announcement from the National Healthcare Security Administration.

Tyvyt (recombinant anti-human PD-1 monoclonal antibody, international trademark: Tyvyt, generic name: sintilimab injection) is an innovative PD-1 inhibitor jointly developed by Lilly and Innovent. 

It was officially approved by National Medical Products Administration on 24 December 2018 and used for the treatment of relapsed or refractory classic Hodgkin's lymphoma after at least second-line system chemotherapy.

Read Innovent Biologics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Market access , China